Korlym Approval History 
- FDA approved: Yes (First approved February 17th, 2012)
- Brand name: Korlym
- Generic name: mifepristone
- Company: Corcept Therapeutics
- Treatment for: Cushing's Syndrome
Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance.
FDA Approval History for Korlym
| Date | Article |
|---|---|
| Feb 17, 2012 |  FDA Approves Korlym for Patients with Endogenous Cushing's Syndrome |
See also...
Korlym (mifepristone) Consumer Information
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
